Financial Data and Key Metrics Changes - The company reported net revenue of $25.8 million for the second quarter, representing a 28% year-over-year growth [5] - Gross profit increased by $5.7 million or 32% to $23.9 million, with gross margin rising approximately 250 basis points to 93% of net revenue [29] - The net loss for the second quarter was $2 million or $0.23 per diluted share, compared to a net loss of $3.5 million or $0.42 per diluted share in the previous year [31] - Adjusted EBITDA for the second quarter was $2.7 million, an increase of $2.1 million or 350% year-over-year [33] Business Line Data and Key Metrics Changes - The Surgical segment generated net revenue of $25.8 million, with soft tissue product sales increasing 28% year-over-year to $22.7 million [5][6] - Bone Fusion products saw a 25% year-over-year increase in sales to $3.1 million [6] - The Surgical segment achieved a net income of approximately $500,000, an improvement of $2.7 million year-over-year [6] - The Tissue Health Plus (THP) segment reported a net loss of $2.5 million, compared to a net loss of $1.3 million last year [32] Market Data and Key Metrics Changes - The company expanded its distributor network to over 400 distributors, up from more than 300 the previous year [18] - The customer base grew to over 1,400 healthcare facilities, compared to more than 1,100 in the prior year [19] - The number of surgeons using the company's products in existing facilities increased significantly, indicating strong growth potential [20] Company Strategy and Development Direction - The company is focused on preserving capital while driving sustainable growth and long-term value creation [14] - A formal process has been initiated to evaluate strategic alternatives for the THP segment, aiming to maximize shareholder value [12][13] - The company plans to reduce cash investment in the THP segment in the second half of 2025 to preserve capital [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the financial resources available to support key growth initiatives, including cash flow from the Surgical segment and available borrowing capacity [35] - The company does not anticipate a material impact from tariffs on operations in 2025 [35] - Management highlighted the importance of expanding clinical evidence for key products to educate the market on their benefits [8] Other Important Information - The company completed the acquisition of CarePix, which is integral to the THP technology platform [22] - The THP pilot program began with a provider group, aiming to validate and optimize the THP technology platform [23][24] - The company achieved two product development milestones under its exclusive license agreement with Biomimetic Innovations Limited [35] Q&A Session Summary Question: How long does it typically take for a new distributor to become productive? - The timeline varies based on market conditions and existing approvals, ranging from days to months [39][40] Question: What is the expected cadence of operating expenses moving into 2026? - The company anticipates THP segment investments between $5.5 million and $6.5 million for the second half of the year [41] Question: Can you provide details on the growth of specific products like CELERATE and BioSurg? - CELERATE and BioSurg are key growth drivers, with both products showing steady growth and significant market potential [48] Question: What are the main drivers for seeking strategic alternatives for THP? - The company is looking for strategic partners to complement its investments and expand the THP product line [52][53]

Financial Data and Key Metrics Changes - Sonera Surgical segment delivered net revenue of $23.4 million, representing a 26% year-over-year growth, driven primarily by a 28% increase in sales of soft tissue repair products to $20.5 million [5][6] - Gross profit increased by $5 million or 30% to $21.6 million, with gross margin rising approximately 240 basis points to 92% of net revenue [21][22] - Net loss for the first quarter was $3.5 million or $0.41 per diluted share, compared to a net loss of $1.8 million or $0.21 per diluted share last year [23][24] - Adjusted EBITDA for the first quarter was $700,000, an increase of 111% year-over-year [24] Business Line Data and Key Metrics Changes - In the Tissue Health Plus segment, the company continues to invest in developing a value-based wound care strategy, preparing to launch a pilot program with a wound care provider later in the second quarter [6][20] - The Synera Surgical segment generated operating income of $800,000 in the first quarter, an increase of $1 million year-over-year [22][24] - Tissue Health Plus segment generated a net loss of $2.9 million compared to a net loss of $1.4 million last year [24] Market Data and Key Metrics Changes - The company expanded its distributor network to over 400 partners, up from over 250 in the first quarter of 2024, enhancing sales coverage in key markets across the US [10][11] - Products were sold in over 1,300 healthcare facilities, compared to over 1,080 facilities in the prior year period [11][12] Company Strategy and Development Direction - The company is focused on three commercial initiatives: advancing distributor relationships, selling into new healthcare facilities, and increasing penetration in existing facilities [10][12] - The company aims to onboard and train additional distributor representatives to increase sales within existing distributor relationships [14][15] - The company is also pursuing financial partners to invest in the execution of its Tissue Health Plus strategy [7][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong start to 2025 and remains focused on delivering net revenue growth, particularly in the Synera Surgical segment [26] - The company does not anticipate a material impact from tariffs on its operations in 2025, as most products are manufactured in the US [27] Other Important Information - The company amended the terms of its debt facility to provide increased financial flexibility [8] - The THP CoPilot software platform was released, designed to standardize wound care and reduce administrative burdens for clinicians [17][18] Q&A Session Summary Question: Can you provide more insight into penetration rates and strategies for improvement? - Management indicated a coupled approach between territory managers and distributor expansion to penetrate existing accounts deeper [30][31] Question: Are there any reorder rates available for the products? - Management noted that while specific reorder rates are not disclosed, once surgeons gain comfort with the products, they tend to continue using them for more procedures [32] Question: How should gross margin be viewed for the remainder of 2025? - Management suggested that while there may not be significant additional leverage on gross margin, consistency in modeling is advisable [36][37] Question: What metrics will define success for the initial pilot program in Tissue Health Plus? - Success will be measured through clinician adherence to protocols, reduction in post-encounter time, staff productivity, and user satisfaction metrics [41][44]

Financial Data and Key Metrics Changes - The company reported net revenue of $23.4 million for Q1 2025, representing a 26% year-over-year growth, driven primarily by a 28% increase in sales of soft tissue repair products to $20.5 million [5][6] - Gross profit increased by $5 million or 30% to $21.6 million, with gross margin rising approximately 240 basis points to 92% of net revenue [22] - The net loss for Q1 2025 was $3.5 million or $0.41 per diluted share, compared to a net loss of $1.8 million or $0.21 per diluted share in the previous year [24] Business Line Data and Key Metrics Changes - In the Synera Surgical segment, adjusted EBITDA increased by $1.5 million year-over-year to $2.7 million, while the net loss increased by $200,000 to $600,000 [6][24] - The Tissue Health Plus segment reported a net loss of $2.9 million, up from a net loss of $1.4 million in the previous year, with a segment adjusted EBITDA loss of $2 million compared to a loss of $900,000 last year [24] Market Data and Key Metrics Changes - The company expanded its distributor network to over 400 partners, up from over 250 in Q1 2024, enhancing sales coverage in key markets across the U.S. [10] - The number of healthcare facilities served increased to over 1,300, compared to over 1,080 facilities in the prior year [11] Company Strategy and Development Direction - The company is focused on enhancing its new product pipeline and has secured distribution rights to two additional technologies [7] - The strategy includes investing in the Tissue Health Plus segment and launching a pilot program with a wound care provider later in Q2 2025 [6][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth opportunities ahead, particularly in the Synera Surgical segment, and expects improvements in profitability for 2025 [27] - The company is actively seeking financial partners to support the execution of its Tissue Health Plus strategy [27] Other Important Information - The company amended the terms of its debt facility to provide increased financial flexibility [7] - As of March 31, 2025, the company had $20.7 million in cash and $42.8 million in principal debt obligations outstanding [25] Q&A Session Summary Question: Can you provide more details on your penetration rates and strategy for improving penetration at existing facilities? - The company employs a coupled approach between regional sales managers and distributor expansion to penetrate existing accounts deeper [31] Question: Are there any signals on reorder rates for your products? - The company has not provided specific reorder rates but noted that once surgeons gain comfort with their products, they tend to continue using them across more procedures [33] Question: How should we think about gross margin cadence through the remainder of 2025? - Management indicated that while there may not be significant further leverage on gross margins, consistency with past modeling is advisable [38] Question: What metrics will define success for the pilot program in Tissue Health Plus? - Success will be measured through clinician-facing metrics, operational metrics, and adoption metrics, including protocol adherence and clinician satisfaction [41][45]